Pharmacy Medical Policy Updates
The following Pharmacy Medical Policy programs were updated on Jan. 1, 2026 and will take effect on Feb. 1, 2026:
Prescription Drug Policies
- Anzupgo
- Biologic Immunomodulators
- Elagolix/Relugolix
- Filsuvez
- Hepatitis C Direct Acting Antivirals
- Isturisa
- Korlym
- Myalept
- Otezla
- Parathyroid Hormone Analogs for Osteoporosis
- Phenylketonuria
- Procysbi
- Recorlev
- Sensipar
- Sohonos
- Somatostatin Analog
- Sucraid
- Topical Doxepin
- Vasomotor Symptoms
- Voxzogo
- Winlevi
- Yorvipath
- Zeposia
To view prescription drug policies specific to a formulary or medication list, please select that formulary on the Prior Authorization page of our website.
Medical Pharmacy Solutions Program Policies
- Abecma
- Adcetris
- Aflibercept
- Aucatzyl
- Breyanzi
- Carvykti
- Darzalex_IV
- Erbitux
- Evkeeza
- GCSF_LA
- GCSF_SA
- IVIG
- Keytruda_IV
- Keytruda_SQ
- Kimmtrak
- Krystexxa
- Kymriah
- Libtayo
- Niktimvo
- Ryoncil
- Rytelo
- Tecartus
- Tecentriq_IV
- Tecentriq_SQ
- Tremfya
- Ustekinumab
- Yescarta
- Zepzelca
To access Medical Pharmacy Solutions policies, please visit the Medical Pharmacy Policies (GatewayPA) page.
For additional questions, please refer to the Prior Authorization section of our website or contact your BCBSKS provider relations representative.